2025-2034 Buccal Drug Delivery System Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Buccal Drug Delivery System Market Through 2025?
In recent times, the buccal drug delivery system market size has experienced substantial growth. It is projected to expand from $3.55 billion in 2024 to $3.89 billion in 2025, with a compound annual growth rate (CAGR) of 9.5%. The significant growth during the historic period is largely due to early advancements in drug delivery, adoption by the pharmaceutical industry, clinical studies, and effectiveness, strategies for market penetration, and disease-specific applications.

What's the Projected Size of the Global Buccal Drug Delivery System Market by 2029?
The market for buccal drug delivery systems is predicted to witness significant expansion in the coming years, reaching a value of $5.88 billion by 2029, registering a compound annual growth rate (CAGR) of 10.9%. The anticipated growth during the forecast period can be associated with factors such as the emphasis on patient-oriented drug delivery, an increase in the elderly population, the growing need for targeted treatments, the use of biologics and peptides, as well as regulatory approvals and support. Further investment in research and development also plays a role. Upcoming trends in the forecast period include an increase in patient comfort and adherence, advancements in medication formulations, a surge in chronic illnesses, as well as enhanced focus on pediatric and geriatric care, and better bioavailability.

View the full report here:
https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

Top Growth Drivers in the Buccal Drug Delivery System Industry: What's Accelerating the Market?
The projected increase in chronic disease incidences is anticipated to fuel the expansion of the buccal drug delivery systems market. Chronic diseases, including cancer, heart disease, stroke, diabetes, and arthritis, are conditions that occur for a year or more and are among the most common long-term illnesses. These diseases, although manageable, have no cure and require ongoing medical care and nutritional support. Buccal drug delivery systems offer an optimal solution for administering mucosal and transmucosal drugs, commonly needed by patients with chronic conditions like diabetes and cancer. For instance, as per the World Health Organization, an agency of the United Nations based in Switzerland, there were 41 million deaths caused by non-communicable diseases (NCDs) or chronic diseases every year worldwide, which represents 74% of all deaths in September 2023. The deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the emerging prevalence of chronic diseases underpins the expansion of the buccal drug delivery systems market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

What Are the Key Trends Driving Buccal Drug Delivery System Market Growth?
In the realm of buccal drug delivery systems, key players are focusing their efforts on the development of cutting-edge solutions. One example of such innovation is the oral medication for plaque psoriasis - a condition characterized by a rapid growth of skin cells that lead to thick, red, scaly patches on the skin. Companies aim to enhance the efficacy of drug delivery and ultimately foster better patient outcomes. A significant development took place in September 2022, when Bristol Myers Squibb, a pharmaceutical firm based in the US, obtained FDA approval for its product - Sotyktu (deucravacitinib). This drug, an oral treatment for adults suffering from moderate-to-severe plaque psoriasis, represents the first new oral therapy introduced for this condition in the last ten years. It presents a unique mechanism of action as it selectively inhibits tyrosine kinase 2 (TYK2).

What Are the Main Segments in the Buccal Drug Delivery System Market?
The buccal drug delivery system market covered in this report is segmented -

1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

Which Top Companies are Driving Growth in the Buccal Drug Delivery System Market?
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, ere*x Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

Which Regions Will Dominate the Buccal Drug Delivery System Market Through 2029?
North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.